MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Incidental Lewy Body disease and idiopathic Parkinson’s disease: from common pathogenic factors to the overlapping clinical features

    E. Sansa, T. Warner, E. Depablo Fernandez (London, United Kingdom)

    Objective: To compare established early symptoms and risk factors associated with Parkinson’s disease (PD) in a cohort of incidental Lewy Body disease (iLBD) and healthy…
  • 2022 International Congress

    Impact of the delayed diagnosis in the prognosis of Parkinson’s disease.

    E. Ichikawa-Escamilla, AJ. Hernández-Medrano, P. Bazán-Rodríguez, E. Reséndiz-Henríquez, GI. Cerda-Hernández, MA. Ruíz-Mafud, RA. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

    Objective: To evaluate the difference of motor and non-motor dysfunction, and quality of life in Parkinson’s disease (PD) patients with and without delayed diagnosis. Background:…
  • 2022 International Congress

    Different longitudinal manifestations in dopaminergic dysfunction in REM sleep behavior disorder

    P. Wu, H. Yu (Shanghai, China)

    Objective: To explore the different patterns of dopaminergic dysfunction between iRBD patients who convert to Parkinson’s disease (PD)/dementia with Lewy bodies (DLB) and those who…
  • 2022 International Congress

    A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…
  • 2022 International Congress

    Action verb use in PD: A challenge to the embodied cognition hypothesis?

    E. Nascimento Andrade, C. Manxhari, K. Smith (Worcester, USA)

    Objective: To characterize action verb production in Parkinson's disease (PD) during a picture description task, and evaluate associations with motor and cognitive function. Background: The…
  • 2022 International Congress

    Drivers of burden over time in caregivers of patients with Parkinson’s disease and related disorders: Findings from a community-based clinical trial of outpatient palliative care

    A. Glickman, Z. Macchi, S. Sillau, M. Katz, S. Pantilat, B. Kluger (Aurora, USA)

    Objective: To identify predictors of accelerated caregiver burden in patient-caregiver dyads of people with Parkinson’s disease and related disorders (PDRD). Background: PDRD are characterized by…
  • 2022 International Congress

    Mindfulness based program for newly diagnosed Parkinson’s patients.

    A. Shaji, A. Lasker, N. Ko, M. Solanki, P. Kaur, Y. Ocasio, C. Fanning (Bethlehem, USA)

    Objective: To investigate the impact of 8-week course of Mindfulness based intervention program on motor and or non-motor symptoms of PD assessed by improvement in…
  • 2022 International Congress

    Relationship between falls and motor state in Parkinson’s disease patients with motor fluctuations

    Y. Okuma (Izunokuni, Japan)

    Objective: To elucidate in which motor state Parkinson’s disease (PD) patients with motor fluctuations fall. Background: Recurrent falls are a disabling feature of PD and…
  • 2022 International Congress

    Social Withdrawal in Parkinson’s Disease: A Scoping Review

    S. Ahn, K. Springer, J. Gibson (Charlottesville, USA)

    Objective: We conducted a scoping review to understand the nature and impacts of social withdrawal in PD and identify evidence gaps. Background: Social withdrawal has…
  • 2022 International Congress

    Effect of clinical levodopa medication cycle on subthalamic beta band power during therapeutic deep brain stimulation in Parkinson’s disease

    L. Hammer, C. Oehrn, S. Cernera, A. Hahn, M. Shcherbakova, C. Smyth, S. Little, P. Starr (San Francisco, USA)

    Objective: To characterize the effect of levodopa medication cycle on subthalamic nucleus (STN) local field potential (LFP) beta-band power in Parkinson’s disease (PD) in the…
  • « Previous Page
  • 1
  • …
  • 455
  • 456
  • 457
  • 458
  • 459
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley